Identification of predictive markers of response in colorectal cancer following treatment with dasatinib, an orally active tyrosine kinase inhibitor of ABL and SRC

Autor:	Judy Dering, Amrita Desai, Ondrej Kalous, DJ Slamon, Richard S. Finn, J. R. Hecht, E. Clark, Zev A. Wainberg, Charles Ginther, Adrian Anghel
Rok vydání:	2008
Předmět:	Cancer Research ABL medicine.drug_class business.industry Colorectal cancer medicine.disease Tyrosine-kinase inhibitor Dasatinib Orally active Oncology hemic and lymphatic diseases medicine Cancer research business medicine.drug Proto-oncogene tyrosine-protein kinase Src
Zdroj:	Journal of Clinical Oncology. 26:14688-14688
ISSN:	1527-7755 0732-183X
Popis:	14688 Background: Elevated levels of Src kinase have been implicated in the malignant potential of colorectal cancer. Dasatinib is an orally active, multi-targeted tyrosine kinase inhibitor of ABL ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0d1e4f51730968af6b582d7b30811893 https://doi.org/10.1200/jco.2008.26.15_suppl.14688 Zobrazit plný text záznamu